UCL and Syncona have both returned for Freeline's series B round, which will spur clinical development of the spinout's gene therapy for haemophilia B.
Freeline Therapeutics, a UK-based gene therapy spinout from University College London (UCL) and commercialisation firm Syncona, received £88.4m ($116m) yesterday in a series B round backed by both founding partners.
UCL contributed $4.5m through its Technology Fund, while Syncona provided $112m. Syncona remains Freeline’s only institutional investor with an 80% equity stake, valued at $83.6m post-money, following the first tranche of the series B round.
Founded in 2015, Freeline is developing adeno-associated virus (AAV)-based gene therapies that target…
